The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: Longitudinal data from the INSIGHTS-IPF registry

Respiratory Research

Volumn 20, Issue 1, 2019, Pages

  Kreuter, Michael ^a,z   Swigris, Jeff ^b   Pittrow, David ^c   Geier, Silke ^d   Klotsche, Jens ^e   Prasse, Antje ^f,g,z   Wirtz, Hubert ^h   Koschel, Dirk ⁱ   Andreas, Stefan ^j   Claussen, Martin ^k,z   Grohé, Christian ^l   Wilkens, Henrike ^m   Hagmeyer, Lars ⁿ   Skowasch, Dirk ^o   Meyer, Joachim F ^p   Kirschner, Joachim ^q   Gläser, Sven ^r,s   Kahn, Nicolas ^a,z   Welte, Tobias ^f,z   Neurohr, Claus ^t,x   Schwaiblmair, Martin ^u   Held, Matthias ^v   Bahmer, Thomas ^k,z   Oqueka, Tim ^y   Frankenberger, Marion ^t,w,z   Behr, Jürgen ^t,w,z   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b DEPARTMENT OF MEDICINE   (United States)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^h UNIVERSITY HOSPITAL LEIPZIG   (Germany)

ⁱ Fachkrankenhaus Coswig   (Germany)

^j UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^k LungenClinic Grosshansdorf   (Germany)

^l Klinik fur Pneumologie   (Germany)

^m SAARLAND UNIVERSITY   (Germany)

ⁿ Krankenhaus Bethanien Solingen   (Germany)

^o UNIVERSITY HOSPITAL BONN   (Germany)

^p Munich Municipal Hospital   (Germany)

^q Center for Internal Medical Studies CIMS   (Germany)

^r UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^s Vivantes Klinikum Spandau   (Germany)

^t LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^u KLINIKUM AUGSBURG   (Germany)

^v Missionsärztliche Klinik Würzburg Abteilung Innere Medizin   (Germany)

^w ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^x ROBERT BOSCH HOSPITAL   (Germany)

^y UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^z German Center for Lung Research   (Germany)

more..

Author keywords

Cohort study; Idiopathic pulmonary fibrosis; Patient related outcomes; SQRQ

Indexed keywords

AGED; ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; EQ 5D VAS SCORE; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; GERMAN (CITIZEN); HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PREDICTION; QUALITY OF LIFE; REGISTER; SCORING SYSTEM; SURVIVOR; UCSD SOBQ SCORE; WHO 5 SCORE; CLINICAL TRIAL; COHORT ANALYSIS; DIAGNOSTIC IMAGING; FACTUAL DATABASE; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; PSYCHOLOGY; TIME FACTOR; TRENDS; VITAL CAPACITY;

AGED; COHORT STUDIES; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; QUALITY OF LIFE; REGISTRIES; TIME FACTORS; VITAL CAPACITY;

EID: 85062976631     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/s12931-019-1020-3     Document Type: Article

References (30)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.
2. Behr J, Kreuter M, Hoeper MM, Wirtz H, Klotsche J, Koschel D, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J. 2015;46:186-96.
3. Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015;46:1113-30.
4. Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, et al. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS One. 2016;11:e0151425.
5. Bajwah S, Ross JR, Peacock JL, Higginson IJ, Wells AU, Patel AS, et al. Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature. Thorax. 2013;68:867-79.
6. Glaspole IN, Chapman SA, Cooper WA, Ellis SJ, Goh NS, Hopkins PM, et al. Health-related quality of life in idiopathic pulmonary fibrosis: data from the Australian IPF registry. Respirology. 2017;22:950-6.
7. Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res. 2017;18:139.
8. Yount SE, Beaumont JL, Chen SY, Kaiser K, Wortman K, Van Brunt DL, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. Lung. 2016;194:227-34.
9. Szentes BL, Kreuter M, Bahmer T, Birring SS, Claussen M, Waelscher J, et al. Quality of life assessment in interstitial lung diseases:a comparison of the disease-specific K-BILD with the generic EQ-5D-5L. Respir Res. 2018;19:101.
10. Bahmer T, Kirsten AM, Waschki B, Rabe KF, Magnussen H, Kirsten D, et al. Clinical correlates of reduced physical activity in idiopathic pulmonary fibrosis. Respiration. 2016;(91):497-502.
11. Furukawa T, Taniguchi H, Ando M, Kondoh Y, Kataoka K, Nishiyama O, et al. The St. George's respiratory questionnaire as a prognostic factor in IPF. Respir Res. 2017;18:18.
12. Kreuter M, Bendstrup E, Russell AM, Bajwah S, Lindell K, Adir Y, et al. Palliative care in interstitial lung disease: living well. Lancet Respir Med. 2017;5:968-80.
13. Behr J, Hoeper MM, Kreuter M, Klotsche J, Wirtz H, Pittrow D. Characteristics and management of idiopathic pulmonary fibrosis: INSIGHTS-IPF registry. Dtsch Med Wochenschr. 2012;137:2586-8.
14. Behr J, Hoeper MM, Kreuter M, Klotsche J, Wirtz H, Pittrow D. Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry. BMJ Open Respir Res. 2014;1:e000010.
15. Swigris JJ, Esser D, Wilson H, Conoscenti CS, Schmidt H, Stansen W, et al. Psychometric properties of the St George's respiratory questionnaire in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2017;49:1601788.
16. Swigris JJ, Wilson H, Esser D, Conoscenti CS, Stansen W, Kline Leidy N, et al. Psychometric properties of the St George's respiratory questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials. BMJ Open Respir Res. 2018;5:e000278.
17. Swigris JJ, Han M, Vij R, Noth I, Eisenstein EL, Anstrom KJ, et al. The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med. 2012;106:144-55.
18. Swigris JJ, Esser D, Conoscenti CS, Brown KK. The psychometric properties of the St George's respiratory questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes. 2014;12:124.
19. Yorke J, Jones PW, Swigris JJ. Development and validity testing of an IPF-specific version of the St George's respiratory questionnaire. Thorax. 2010;65:921-6.
20. Moor CC, Heukels P, Kool M, Wijsenbeek MS. Integrating patient perspectives into personalized medicine in idiopathic pulmonary fibrosis. Front Med (Lausanne). 2017;4:226.
21. Yorke J, Spencer LG, Duck A, Ratcliffe S, Kwong GN, Longshaw MS, et al. Cross-Atlantic modification and validation of the a tool to assess quality of life in idiopathic pulmonary fibrosis (ATAQ-IPF-cA). BMJ Open Respir Res. 2014;1:e000024.
22. Jo HE, Glaspole I, Moodley Y, Chapman S, Ellis S, Goh N, et al. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. BMC Pulm Med. 2018;18:19.
23. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071-82.
24. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083-92.
25. Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS((R)) trials. Respir Med. 2016;113:74-9.
26. Idiopathic Pulmonary Fibrosis Clinical Research N, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363:620-8.
27. Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ, INSTAGE Investigators. Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2018;379:1722-31.
28. Bahmer T, Kirsten AM, Waschki B, Rabe KF, Magnussen H, Kirsten D, et al. Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis. BMC Pulm Med. 2017;17:104.
29. Tonelli R, Cocconcelli E, Lanini B, Romagnoli I, Florini F, Castaniere I, et al. Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: a multicenter prospective study. BMC Pulm Med. 2017;17:130.
30. Gomes-Neto M, Silva CM, Ezequiel D, Conceicao CS, Saquetto M, Machado AS. Impact of pulmonary rehabilitation on exercise tolerance and quality of life in patients with idiopathic pulmonary fibrosis: a SYSTEMATIC REVIEW AND META-ANALYSIS. J Cardiopulm Rehabil Prev. 2018;38:273-8.